Sanofi said it has also asked a court to prohibit Sun Pharmaceuticals of India from marketing a generic oxaliplatin product over the same period as the other companies.
The settlement agreements are subject to review by the U.S. Federal Trade Commission, the U.S. Department of Justice and Michigan's attorney general.
Sanofi didn't give more details or reveal financial terms of the deals.
Daiichi Sankyo /zigman2/quotes/207030186/delayed JP:4568 +1.03%
Japanese Application Filed
For Blood-Clot Treatment
Daiichi Sankyo /zigman2/quotes/207150912/delayed JP:4658 +0.38% Co. said it has filed a new drug application in Japan for Edoxaban, an important step in commercializing the treatment to prevent blood clots.
The Tokyo-based company said it is seeking approval of the drug, which is taken orally, for use in the prevention of blood clotting in the veins of patients who have undergone knee- and hip-replacement surgery.
Daiichi Sankyo is also conducting clinical trials on Edoxaban for people at risk of developing clots in veins due to blood coagulation or in arteries due to irregular heartbeats.
When Daiichi Sankyo eventually develops Edoxaban for patients with irregular heartbeats, it would be able to tap into the lucrative market for atrial-fibrillation treatment, which analysts estimate exceeds $15 billion a year globally.
Names Operating Chief
National carrier Air India appointed Gustav Baldauf as its first chief operating officer, and as the first expatriate in the state-owned airline's management, a company executive said Tuesday.
Mr. Baldauf is currently senior director for marketing at Air Canada and his joining date is yet to be decided, said K. Swaminathan, deputy general manager for corporate communications at the unprofitable carrier. He said the appointment was decided during Tuesday's board meeting.
Air India also decided that Chairman and Managing Director Arvind Jadhav and Mr. Baldauf will come up with a turnaround plan for the carrier in the next 30 days.
"The plan will then be presented to the independent directors recently included in the company's board," Mr. Swaminathan said.
Auto Maker Extends
Incentives for Customers
Toyota Motor /zigman2/quotes/200537742/composite TM +1.78% Corp. extended its March customer-incentive program into April and broadened its complimentary maintenance program to all buyers, as the Japanese auto maker seeks to maintain sales momentum in the face of its recall crisis.
Through May 3, Toyota will offer free financing for five years on six models, two-year free maintenance for all customers and low lease rates, the company said in a statement.
Helped by uncharacteristically high incentives in March, Toyota chalked up a 41% increase in U.S. sales from a year earlier.
That made it the second-best-selling auto maker for the month, suggesting that many Toyota buyers were unperturbed by its recall of more than six million vehicles in the U.S. for sticky accelerators and other issues.
While Toyota's March incentives were below those offered by U.S. competitors, they were 44% more than what the company offered in March a year ago, according to the car-shopping Web site Edmunds.com.